Literature DB >> 25201862

Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody.

Husein Husein-ElAhmed1, Jose Luis Callejas-Rubio, Raquel Rios-Fernandez, Norberto Ortego-Centeno.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201862     DOI: 10.4103/0378-6323.140335

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  6 in total

1.  Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus.

Authors:  Renee Fruchter; Drew J B Kurtzman; Mital Patel; Joseph Merola; Andrew G Franks; Ruth Ann Vleugels; Alisa N Femia
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

2.  [37-year-old male with confluent papules and arcuate erythematosquamous plaques on the upper trunk and arms : Preparation for the specialist examination: part 22].

Authors:  M Meurer; C Günther
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 3.  Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

Authors:  Joshua Chang; Victoria P Werth
Journal:  Expert Rev Clin Immunol       Date:  2016-06-01       Impact factor: 4.473

Review 4.  Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.

Authors:  Jasmine N Stannard; J Michelle Kahlenberg
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

Review 5.  [Lupus erythematosus].

Authors:  C Günther; S Beissert
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 6.  Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.

Authors:  Carlos Rodríguez Escalera; Ángela María Zurita Guisado; Francisco Javier Mateo; Noemí Bahamontes-Rosa; María Jesús García Villanueva
Journal:  Clin Rheumatol       Date:  2022-07-23       Impact factor: 3.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.